Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol and Atorvastatin Effects on Platelet Reactivity in Diabetes
NCT03195153Phase 4
Key facts
- Status
- Unknown
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Countries
- 1
- Sponsor
- Sapienza University of Rome
- Modality
- Small Molecules
- Drugs
- allopurinol
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 4, randomised trial of allopurinol in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sapienza University of Rome. Primary endpoint: Assessment of platelet reaction units Absolute changes in platelet reactivity at 30 days. Status: unknown.
02
Design
3 arms- Study design
- Randomized
Statin Only
Atorvastatin 80mg
Allopurinol Only
Allopurinol 300mg
Statin + Allopurinol
Atorvastatin 80mg + Allopurinol 300mg
03
Who it enrols
Diabetic patients treated with aspirin and insulin who are 'well responders'. Patients with severe renal failure or who are 'poor responders' are excluded.
04
Endpoints
Primary
Assessment of platelet reaction units Absolute changes in platelet reactivity
Beyond the preview
Go deeper on NCT03195153.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195153.